Researchers at Karolinska Institutet and Lund University in Sweden have identified a new treatment strategy for neuroblastoma, an aggressive form of childhood cancer. By combining two antioxidant ...

The MYCN oncoprotein plays a key role in starting, advancing and making it difficult to treat various human cancers. When MYCN is overactive, especially in high-risk neuroblastoma, the tumors become ...

Neuroblastoma can be a particularly insidious cancer. In about half of all cases, tumors regress, even without therapy. In the other half, tumors grow very quickly. These tumors often respond well to ...

In 2017, Stephanie Uy learned that her 22-month-old daughter, Aspen, had stage IV high-risk neuroblastoma. The cancer, which develops from the sympathetic nervous system, is the most common type of ...

Preclinical study demonstrates effectiveness of experimental mRNA vaccine against neuroblastoma, reducing tumour size by 70 ...

Neuroblastoma is the most common childhood tumor occurring outside the brain. Until now, studying genetic changes and their role in neuroblastoma initiation has been challenging due to the lack of ...

A new study from RCSI University of Medicine and Health Sciences demonstrates a novel approach in anticancer vaccine development. Results present the first preclinical evidence to show the efficacy of ...

For a child diagnosed with neuroblastoma—the most common infant cancer, occurring when early nerve cells grow out of control—the path to treatment isn't simple. Some types of neuroblastoma resolve on ...

All 3-week-old Th-MYCN mice exhibited neuroblast hyperplasia in the superior mesenteric ganglion (SMG), but this was no longer detectable in some mice by 6 weeks of age. Furthermore, while 80% of ...